Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s share price dropped 3% during trading on Thursday . The stock traded as low as $417.50 and last traded at $428.08, with a volume of 1,123,488 shares changing hands. The stock had previously closed at $441.37.

Several brokerages have commented on REGN. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $436.00 to $415.00 in a research note on Friday, April 8th. Leerink Swann restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 9th. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 12th. Brean Capital restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 12th. Finally, Cowen and Company restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, April 17th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and fourteen have given a buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $508.92.

The stock’s 50-day moving average price is $378.14 and its 200 day moving average price is $390.56. The stock has a market capitalization of $45.20 billion and a PE ratio of 68.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.17. During the same period last year, the business earned $2.89 earnings per share. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.24 billion. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals Inc. will post $10.82 earnings per share for the current year.

In related news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the sale, the director now directly owns 15,125 shares of the company’s stock, valued at $6,428,125. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Sanofi bought 64,731 shares of the firm’s stock in a transaction that occurred on Tuesday, June 14th. The shares were purchased at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The disclosure for this purchase can be found here.

A number of large investors recently added to or reduced their stakes in the stock. Brown Advisory Inc. increased its stake in Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Brown Advisory Inc. now owns 1,920 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 58 shares during the last quarter. Bank of Montreal Can increased its stake in Regeneron Pharmaceuticals by 4.8% in the fourth quarter. Bank of Montreal Can now owns 41,944 shares of the biopharmaceutical company’s stock worth $22,770,000 after buying an additional 1,933 shares during the last quarter. Aberdeen Asset Management PLC UK increased its stake in Regeneron Pharmaceuticals by 15.9% in the fourth quarter. Aberdeen Asset Management PLC UK now owns 19,430 shares of the biopharmaceutical company’s stock worth $10,203,000 after buying an additional 2,666 shares during the last quarter. Schroder Investment Management Group increased its stake in Regeneron Pharmaceuticals by 122.1% in the fourth quarter. Schroder Investment Management Group now owns 25,011 shares of the biopharmaceutical company’s stock worth $13,578,000 after buying an additional 13,749 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 1,067 shares during the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.